Online inquiry

IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3087MR)

This product GTTS-WQ3087MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FASLG gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000639.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 356
UniProt ID Q53ZZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3087MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4107MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ1380MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ3865MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ13138MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ13630MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ15020MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ5153MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ14779MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-40
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW